OBJECTIVES: To determine whether Radiofrequency Ablation (RFA) followed by Radiotherapy (RT) (RFA-RT) produces better palliation in terms of pain than RT alone in patients with osteolytic bone metastases. METHODS: Patients with solitary bone metastases and a pain score of least 5 or more on the VAS scale were selected. Fifteen patients were treated with RFA-RT (20 Gy delivered in 5 fractions of 4 Gy over 1 week) and were compared with a matched group (30 subjects) treated by RT. RESULTS: A complete response in terms of pain relief at 12 weeks was documented in 16.6% (5/30) and 53.3% (8/15) of the subjects treated by RT or RFA-RT, respectively (p = 0.027). The overall response rate at 12 weeks was 93.3% (14 patients) in the group treated by RFA-RT and 59.9% (18 patients) in the group treated by RT (p = 0.048). Although recurrent pain was documented more frequently after RT (26.6%) than after RFA-RT (6.7%) the difference did not reach statistical significance. The morbidity related to RT did not significantly differ when this treatment was associated with RFA. CONCLUSIONS: Our results suggest that RFA-RT is safe and more effective than RT. The findings described here should serve as a framework around which to design future clinical trials.
OBJECTIVES: To determine whether Radiofrequency Ablation (RFA) followed by Radiotherapy (RT) (RFA-RT) produces better palliation in terms of pain than RT alone in patients with osteolytic bone metastases. METHODS:Patients with solitary bone metastases and a pain score of least 5 or more on the VAS scale were selected. Fifteen patients were treated with RFA-RT (20 Gy delivered in 5 fractions of 4 Gy over 1 week) and were compared with a matched group (30 subjects) treated by RT. RESULTS: A complete response in terms of pain relief at 12 weeks was documented in 16.6% (5/30) and 53.3% (8/15) of the subjects treated by RT or RFA-RT, respectively (p = 0.027). The overall response rate at 12 weeks was 93.3% (14 patients) in the group treated by RFA-RT and 59.9% (18 patients) in the group treated by RT (p = 0.048). Although recurrent pain was documented more frequently after RT (26.6%) than after RFA-RT (6.7%) the difference did not reach statistical significance. The morbidity related to RT did not significantly differ when this treatment was associated with RFA. CONCLUSIONS: Our results suggest that RFA-RT is safe and more effective than RT. The findings described here should serve as a framework around which to design future clinical trials.
Authors: M Di Staso; L Zugaro; G L Gravina; P Bonfili; F Marampon; L Di Nicola; A Conchiglia; P Franzese; M Gallucci; C Masciocchi; V Tombolini Journal: Clin Oncol (R Coll Radiol) Date: 2010-11-23 Impact factor: 4.126
Authors: S Nahum Goldberg; Clement J Grassi; John F Cardella; J William Charboneau; Gerald D Dodd; Damian E Dupuy; Debra Gervais; Alice R Gillams; Robert A Kane; Fred T Lee; Tito Livraghi; John McGahan; David A Phillips; Hyunchul Rhim; Stuart G Silverman Journal: Radiology Date: 2005-04-21 Impact factor: 11.105
Authors: Nora Janjan; Stephen T Lutz; John M Bedwinek; William F Hartsell; Andrea Ng; Richard S Pieters; Vaneerat Ratanatharathorn; Edward B Silberstein; Robert J Taub; Alan W Yasko; Andrew Rettenmaier Journal: J Palliat Med Date: 2009-05 Impact factor: 2.947
Authors: S S Lo; A Sahgal; W F Hartsell; S T Lutz; D Kardamakis; Y van der Linden; P J Hoskin Journal: Clin Oncol (R Coll Radiol) Date: 2009-09-09 Impact factor: 4.126
Authors: Edward Chow; Jackson S Y Wu; Peter Hoskin; Lawrence R Coia; Soren M Bentzen; Peter H Blitzer Journal: Radiother Oncol Date: 2002-09 Impact factor: 6.280
Authors: Matthew P Goetz; Matthew R Callstrom; J William Charboneau; Michael A Farrell; Timothy P Maus; Timothy J Welch; Gilbert Y Wong; Jeff A Sloan; Paul J Novotny; Ivy A Petersen; Robert A Beres; Daniele Regge; Rodolfo Capanna; Mark B Saker; Dietrich H W Grönemeyer; Athour Gevargez; Kamran Ahrar; Michael A Choti; Thierry J de Baere; Joseph Rubin Journal: J Clin Oncol Date: 2004-01-15 Impact factor: 44.544
Authors: Matthew R Callstrom; J William Charboneau; Matthew P Goetz; Joseph Rubin; Gilbert Y Wong; Jeff A Sloan; Paul J Novotny; Bradley D Lewis; Timothy J Welch; Michael A Farrell; Timothy P Maus; Robert A Lee; Carl C Reading; Ivy A Petersen; Deitra D Pickett Journal: Radiology Date: 2002-07 Impact factor: 11.105
Authors: Adam N Wallace; Ross Vyhmeister; Andy C Hsi; Clifford G Robinson; Randy O Chang; Jack W Jennings Journal: Interv Neuroradiol Date: 2015-10-23 Impact factor: 1.610
Authors: Dimitrios K Filippiadis; Steven Yevich; Frederic Deschamps; Jack W Jennings; Sean Tutton; Alexis Kelekis Journal: Curr Oncol Rep Date: 2019-11-25 Impact factor: 5.075
Authors: Carlo Masciocchi; Francesco Arrigoni; Alice La Marra; Silvia Mariani; Luigi Zugaro; Antonio Barile Journal: Br J Radiol Date: 2016-06-20 Impact factor: 3.039
Authors: Adam N Wallace; Clifford G Robinson; Jeffrey Meyer; Nam D Tran; Afshin Gangi; Matthew R Callstrom; Samuel T Chao; Brian A Van Tine; Jonathan M Morris; Brian M Bruel; Jeremiah Long; Robert D Timmerman; Jacob M Buchowski; Jack W Jennings Journal: Oncologist Date: 2015-09-09
Authors: Carlo Masciocchi; Luigi Zugaro; Francesco Arrigoni; Giovanni Luca Gravina; Silvia Mariani; Alice La Marra; Carmine Zoccali; Stefano Flamini; Antonio Barile Journal: Eur Radiol Date: 2015-11-26 Impact factor: 5.315
Authors: Luigi Zugaro; Mario DI Staso; Giovanni Luca Gravina; Pierluigi Bonfili; Lorenzo Gregori; Pietro Franzese; Francesco Marampon; Vincenzo Tombolini; Ernesto DI Cesare; Carlo Masciocchi Journal: Oncol Lett Date: 2016-01-14 Impact factor: 2.967